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Abstract
 
Sphingomyelinase (SMase) is one of the principal enzymes in sphingomyelin (SM) metabolism.
 
Here, we identified a 
 
Plasmodium falciparum
 
 gene (
 
PfNSM
 
) encoding a 46-kD protein, the amino
 
acid sequence of which is 
 
 
 
25% identical to that of bacteria SMases. Biochemical analyses of the
recombinant protein GST-PfNSM, a fusion protein of the 
 
PfNSM
 
 product with glutathione-S-
transferase, reveal that this enzyme retained similar characteristics in various aspects to SMase de-
tected in 
 
P. falciparum
 
–infected erythrocytes and isolated parasites. In addition, the recombinant
protein retains hydrolyzing activity not only of SM but also of lysocholinephospholipids (LCPL)
including lysophosphatidylcholine and lysoplatelet-activating factor, indicating that 
 
PfNSM
 
 en-
codes SM/LCPL-phospholipase C (PLC). Scyphostatin inhibited SM/LCPL-PLC activities of
the 
 
PfNSM
 
 product as well as the intraerythrocytic proliferation of 
 
P. falciparum
 
 in a dose-depen-
 
dent manner with ID
 
50
 
 values for SM/LCPL-PLC activities and the parasite growth at 3–5 
 
 
 
M
and 
 
 
 
7 
 
 
 
M, respectively. Morphological analysis demonstrated most severe impairment in the
intraerythrocytic development with the addition of scyphostatin at trophozoite stage than at ring
or schizont stages, suggesting its effect specifically on the stage progression from trophozoite to
schizont, coinciding with the active transcription of 
 
PfNSM
 
 gene.
Key words: lysophosphatidylcholine • lysoplatelet-activating factor • 
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Introduction
 
Malaria remains a devastating disease worldwide, especially
in the tropics. 
 
Plasmodium falciparum
 
, the deadliest among
four species of malaria parasites that infect humans, is re-
sponsible for more than a million deaths annually. Emer-
gence and spread of resistant parasites to agents such as
chloroquine and pyrimethamine/sulfadoxine highlights the
need to develop new drugs against this disease. In this
quest, elucidating the differences in metabolisms between
host and parasite at the molecular level would provide
novel targets for malaria chemotherapy.
Lipid metabolism, which is almost nonfunctional in
uninfected erythrocytes (1), rises drastically during in-
traerythrocytic development of malaria parasites (2, 3)
contributing mainly to membrane biogenesis. Membrane
biogenesis includes not only organelle membranes of pro-
liferating parasites but also the tubovesicular membrane
network in the cytoplasm of infected erythrocytes (2, 4).
The parasites meet the demand for the necessary lipid spe-
cies by synthesizing through de novo pathways as well as
acquiring from extracellular sources (2, 5, 6). Parasite
cells, therefore, appear to develop unique features in lipid
metabolism for survival in the intraerythrocytic environ-
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ment, prompting an increase in attention on lipid metabo-
lism to provide rational targets for malaria chemotherapy
(7–10).
Sphingolipids, which are widely distributed in eukary-
otes, play important roles in the growth of cells (11–13).
Sphingomyelin (SM)
 
*
 
 is the most abundant of the mamma-
lian sphingolipids, and degradation of SM to produce cer-
amide appears to be responsible for the modulation of vari-
ous cellular events including proliferation, differentiation,
and apoptosis (14–16). SM is also associated with the plas-
modial parasites (2, 17); however, SM metabolism in para-
site cells is poorly understood.
Sphingomyelinase (SMase) is a principal enzyme cata-
lyzing the hydrolysis of SM to ceramide and phosphocho-
line (18). In mammalian cells, there are two well-known
types of SMase. One is termed acid SMase, with an opti-
mum pH at around 4.8; further subclassified to two iso-
forms, an endosomal/lysosomal acid SMase and a secretory
Zn
 
2
 
 
 
-dependent SMase. The other type of mammalian
SMase, termed neutral SMase, is a membrane-bound and
Mg
 
2
 
 
 
-dependent SMase, with an optimum pH at around
7.5. One isoform of neutral SMase has been recently dem-
onstrated to have substantial phospholipase C (PLC) activ-
ity toward lysophosphatidylcholine (lysoPtdCho) and lyso-
platelet-activating factor (lysoPAF; reference 19). Some
bacteria produce extracellular Mg
 
2
 
 
 
-dependent neutral
SMases (18) that are presumably implicated in degradation
of environmental SM for nutritional use or for infection to
vertebrate hosts. Several cDNAs encoding acid and neutral
SMases (18, 20–23) and genes for bacterial SMase (24–26)
have been identified so far. There has been no report,
however, of a plasmodial SMase gene.
We have recently demonstrated that 
 
P. falciparum
 
–
infected human erythrocytes but not uninfected erythro-
cytes retain the activity of a neutral SMase (27). Here, we
identify and characterize the 
 
P. falciparum
 
 gene encoding a
neutral SMase. The enzyme encoded by the plasmodial
gene retains phospholipase C activity toward lysocholine-
phospholipids (LCPL) as well as SM, and this PLC activity
was inhibited by scyphostatin. In addition, the effect of scy-
phostatin on in vitro culture of 
 
P. falciparum
 
 was investi-
gated to implicate this enzyme with the intraerythrocytic
development of parasite cells.
 
Materials and Methods
 
Materials.
 
Bovine brain SM, sphingosylphosphocholine,
phosphatidylserine (PtdSer), PAF, lysoPAF, 1-monopalmitoyl-
 
rac
 
-glycerol, 1-octadecyl-
 
rac
 
-glycerol, intact BSA (product no.
A-1933), and fatty acid–free BSA (product no. A-7511) were
purchased from Sigma-Aldrich. Fatty acid–free BSA was used as
lipid-free BSA (6). Egg lysoPtdCho was from Avanti Polar Lip-
ids, Inc., and 1-hexadecyl-2-acetyl-
 
sn
 
-glycerol from Biomol Re-
search Laboratories Inc. [
 
Choline-methyl
 
-
 
14
 
C]SM (55 mCi/mmol)
and [
 
choline-methyl
 
-
 
14
 
C]PtdCho l-
 
 
 
-dipalmitoyl (55 mCi/mmol)
were purchased from American Radiolabeled Chemicals Inc.
1-
 
O
 
-[
 
3
 
H]
 
octadecyl
 
 PAF (163 Ci/mmol), 1-
 
O
 
-[
 
3
 
H]
 
octadecyl
 
 lyso-
PAF (163 Ci/mmol), and [8-
 
3
 
H]-hypoxanthine (18–27 Ci/
mmol) were from Amersham Pharmacia Biotech, and [
 
palmitoyl
 
-
1-
 
14
 
C]lysoPtdCho l-1-monopalmitoyl (55 mCi/mmol) from
NEN Life Science Products. Scyphostatin was generously pro-
vided from Sankyo Co. and d, l
 
-threo-
 
1-phenyl-2-hexadecanoid-
ylamino-3-morphiolino-1-propanol (PPMP) was from Matreya,
Inc. Scyphostatin and PPMP were dissolved in DMSO at 10 mM
and stored at –20
 
 
 
C until use. PF1350, a 
 
P. falciparum
 
 expression
sequence tag (EST) clone, was generously provided by Dr. Debo-
pam Chakrabarti (University of Central Florida, Orlando, FL).
 
Parasite Culture. P. falciparum
 
 parasite lines used are 3D7, Hon-
duras-1 (6), Dd2 (28), HB3 (28), and FCR3 (29). 3D7 line was a
generous gift from Dr. Masatsugu Kimura (Osaka City University,
Osaka, Japan). HB3 and Dd2 lines were provided by Dr. Thomas
E. Wellems (National Institutes of Health, Bethesda, MD). Parasite
cells were routinely maintained as described previously (6, 27).
 
5
 
 
 
-Rapid Amplification of cDNA Ends.
 
Parasite cells were iso-
lated from the asynchronous culture of 3D7 line through 0.075%
saponin/PBS (wt/vol) treatment. Total RNA was extracted from
isolated parasites with Trizol (GIBCO BRL). First strand cDNA
was synthesized from 200 ng total RNA with SMART™
5
 
 
 
-Rapid Amplification of cDNA Ends (RACE) cDNA Amplifi-
cation Kit (CLONTECH Laboratories, Inc.) by using the Super-
script II reverse transcriptase (GIBCO BRL). PCR was con-
ducted with Platinum™ Taq polymerase High Fidelity (GIBCO
BRL) using the following conditions in a Peltier Thermal Cy-
cler-200 (MJ Research, Inc.): one initial denaturation cycle at
94
 
 
 
C for 1 min, 10 cycles of denaturation at 94
 
 
 
C for 20 s, an-
nealing and extension at 62
 
 
 
C for 5 min, 1 cycle of extension at
72
 
 
 
C for 10 min proceeded by 35 cycles at 91
 
 
 
C for 30 s, and at
70
 
 
 
C for 5 min, with a final extension cycle at 68
 
 
 
C for 10 min.
The gene specific primer, 5
 
 
 
-GGCGCTTGTAATTGCGAC-
CTATTAC-3
 
 
 
, was used together with universal primers pro-
vided in SMART™ RACE cDNA Amplification Kit.
 
Northern Blotting.
 
Total RNA was extracted from parasite
cells isolated from asynchronous cultures of 3D7, Honduras-1
and Dd2, or synchronized culture of HB3. For the harvest of
ring-rich or trophozoite- and schizont-rich parasite cultures,
tightly synchronized culture of HB3 line within 4 h life span (6)
was further incubated for 12 or 27 h, respectively, and parasite
cells were then isolated by saponin treatment. Extracted total
RNA was fractionated on a 1.2% agarose/formaldehyde gel and
transferred onto Nytran membrane (Schleicher & Schuell). The
membrane was probed with a 744-bp PCR product encoding
the internal region of 
 
PfNSM
 
 open reading frame (ORF), ex-
posed to Fujifilm BAS imaging plate, and analyzed with MacBAS
1500 (Fuji Film Co.). For probe preparation, 5
 
 
 
-CCACA-
CAAATGTAATAGGTCGC-3
 
 
 
 and 5
 
 
 
-GTGTTTATAAT-
TATAATCTCTTTCG-3
 
 
 
 were used for PCR as forward and
reverse primer, respectively.
 
Reverse Transcription PCR.
 
Total RNA was extracted from
parasite cells isolated from a synchronized culture of Honduras-1
line. Tightly synchronized culture of Honduras-1 line within 4 h
life span was further incubated for 1, 20, 25, 30, or 36 h before
saponin treatment. Reverse transcription (RT)-PCR was con-
ducted with GIBCO BRL Superscript™ First-strand Synthesis
System for RT-PCR using 50 ng total RNA. Target cDNA was
 
*
 
Abbreviations used in this paper:
 
 EST, expression sequence tag; GST, glu-
tathione-S-transferase; 
 
K
 
m
 
, Michaelis constant; LCPL, lysocholinephos-
pholipids; ORF, open reading frame; PAF, platelet-activating factor;
PLC, phospholipase C; PPMP, d, l
 
-threo-
 
1-phenyl-2-hexadecanoidyl-
amino-3-morphiolino-1-propanol; PtdCho, phosphatidylcholine; PtdSer,
phosphatidylserine; RACE, rapid amplification of cDNA ends; RT, re-
verse transcription; SM, sphingomyelin; SMase, sphingomyelinase. 
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amplified by the same set of primers used for probe preparation.
For control, primer sets that annealed to the conserved block 3
and 5 of merozoite surface antigen-1 gene (30) was used: 5
 
 
 
-
TTCGTGCAAATGAATTAGACGTAC-3
 
 
 
 (forward primer)
and 5
 
 
 
-GGATCAGTAAATAAACTATCAATGT-3
 
 
 
 (reverse
primer). RNA samples from the different stages that were not
treated with reverse transcriptase gave no PCR products.
 
Plasmid Constructs.
 
PF1350C is a 
 
P. falciparum
 
 cDNA cloned
in pBluescript
 
®
 
 SK (31). For construction of 
 
PfNSM
 
, ATGC-
CAAGAATAG sequence was added to 5
 
 
 
 terminus of PF1350C
by PCR with PF1350C as template DNA, 5
 
 
 
-TAAGGATC-
CGCCACCATGCCAAGAATAGAAATATCAAAAGATGT-
AAAGC-3
 
 
 
 as forward primer, and 5
 
 
 
-TAAATGTACTAG-
GAATTCC-3
 
 
 
 as reverse primer. The amplified fragment was di-
gested with BamHI and EcoRI, and the resulting 0.8 kbp frag-
ment was ligated to a BamHI- and EcoRI-digested 3.7 kbp
fragment from the PF1350C on pBluescript
 
®
 
 SK.
The pGEX-PfNSM was constructed from a BamHI- and
XhoI-digested 1.7 kbp fragment from 
 
PfNSM
 
, transferred to the
multi-cloning sites of pGEX-6P-2 (Amersham Pharmacia Bio-
tech), with the resulting plasmid encoding a fusion protein of
PfNSMase linked to glutathione-S-transferase (GST). To construct
pGEX-PfNSM
 
d
 
(2/68), the sequence encoding the 2–68th amino
acid residues of PfNSMase was deleted from pGEX-PfNSM.
 
Preparation of Cytosol and Membrane Fractions of Escherichia coli
Cells Transfected with pGEX-PfNSM or pGEX-6P-2.
 
Logarith-
mically growing cells of 
 
E. coli
 
 XL1-Blue strain (Stratagene)
transfected with pGEX-PfNSM or pGEX-6P-2 were incubated
in 250 ml Terrific broth containing 50 
 
 
 
g/ml ampicillin and 1
mM isopropyl-1-thio-
 
 
 
-d-galactopyranoside for 90 min at 33
 
 
 
C.
Hereafter, manipulations were performed at 4
 
 
 
C or on ice. Cells
harvested by centrifugation (1,500 
 
g
 
, 15 min) were washed with
20 ml of 10 mM Tris-HCl (pH 8.0) containing 0.1 M NaCl and
1 mM EDTA, and suspended with 10 ml of 25 mM Tris-HCl
(pH 8.0) containing 50 mM glucose and 10 mM EDTA. Egg
white lysozyme was added to the cell suspension at a final con-
centration of 100 
 
 
 
g/ml, and the mixture was incubated for 10
min. After addition of 10 ml HSEI buffer (10 mM Hepes-NaOH
[pH 7.5] containing 0.25 M sucrose, 1 mM EDTA, and a pro-
tease inhibitor cocktail [EDTA-free Complete™ Protease Inhib-
itor; Roche]), the resulting mixture was sonicated five times with
a probe-type sonicator at 20 W for 10 s The sonicated sample
was centrifuged (1500 
 
g
 
, 15 min), and the supernatant fluid was
recovered as cell lysate. Cell lysate was centrifuged (10
 
5
 
 
 
g
 
, 1 h),
and the recovered supernatant and precipitated fractions were
designated as cytosol and membrane fractions, respectively. The
precipitated membranes were suspended in HSEI buffer. Frac-
tions were stored at 
 
 
 
80
 
 
 
C.
 
Assays of PLC Activities toward Various Phospholipids.
 
Assay of
neutral SMase dependent on Mg
 
2  and PtdSer was routinely
performed under detergent-mixed micelle conditions as de-
scribed previously (27). In brief, enzyme sources were incubated
in 50  l of 50 mM Hepes-NaOH (pH 7.5) containing 10 mM
MgCl2, 1 mM bovine brain PtdSer, 0.1% Triton X-100, 0.2%
 -octylglucoside, and 10  M [choline-methyl-14C]SM at 37 C for
30 min. Reaction was stopped by addition of 0.8 ml chloro-
form/methanol (2/1, vol/vol). After phase separation, the radio-
activity partitioned to the upper aqueous phase was measured.
For PtdCho-PLC assay, 10  M [choline-methyl-14C]PtdCho in
place of [choline-methyl-14C]SM was used as a substrate. Under
detergent-free assay condition, radioactive SM or PtdCho was
dispersed in deionized water with a probe-type sonicator be-
fore use.
For other PLC assays, enzymatic reaction was proceeded under
detergent-free condition using 10  M corresponding radioac-
tive substrate, l-1-[palmitoyl-1-14C]lysoPtdCho, 1-O-[3H]octadecyl
PAF or 1-O-[3H]octadecyl lysoPAF. During the phase separation,
20   l monopalmitoylglycerol, 1-hexadecyl-2-acetyl-glycerol or
1-octadecyl-rac-glycerol (1 mg/ml each in chloroform) was added
as a carrier. Lipids recovered in organic phase were developed on
TLC with a solvent system of diethylether/acetic acid (200/1,
vol/vol), and separated radioactive lipids were analyzed with a
BAS2000 or BAS1800 image analyzer, followed by radioactive
measurements of corresponding product with liquid scintillation
counter. In all PLC assays described above, background activities
from the enzyme-free controls, in which vehicle buffers instead of
the enzyme sources were added, were routinely subtracted from
the activities of samples containing enzyme sources.
Growth Inhibition of P. falciparum Cell Lines. In vitro suscepti-
bility of P. falciparum lines to compounds tested was determined
by [3H]hypoxanthine uptake assay (32) using either a modified
standard medium or a serum-free medium supplemented with
various concentrations of the test compounds. The modified
standard medium is a basic medium (27) without hypoxanthine
containing 10% human serum, whereas the serum-free medium
was prepared as follows: lipid-free BSA powder was dissolved in a
hypoxanthine-free basic medium to adjust to 30  M, and then
supplemented with 7.4 mM hypoxanthine and 600  M intact
BSA solutions (6) at 0.1% and 10% (vol/vol), respectively. Para-
site cultures synchronized to ring stage with 5% d-sorbitol (33)
was adjusted to  0.5% parasitemia at 3% hematocrit in 100  l
volume per well. After 24 h incubation, 25  l of either medium
containing 20  Ci [3H]hypoxanthine was added into each well
and the culture was incubated for another 24 h before harvesting.
The parasitemia was also determined microscopically (6).
Effect of Compounds on the Intraerythrocytic Development of P. falci-
parum. A tightly synchronized culture of P. falciparum Hondu-
ras-1 line within 4 h life span was prepared, and adjusted to  1%
rings at 3% hematocrit in the modified serum-free medium with
370  M hypoxanthine and 0.1% DMSO. At the time indicated,
the medium was replaced with prewarmed medium containing
either 1  M scyphostatin or 5  M PPMP in place of 0.1%
DMSO and the parasite culture was maintained until 52 h. Gi-
emsa-stained thin-blood smears were prepared from the culture
at various times. To prevent nutrient deprivation, the medium
was changed every 12 h.
Miscellaneous. Anti-PfNSMase antiserum was prepared by
immunization of rabbits with synthetic peptides corresponding to
the 134–152th amino acid residues of PfNSMase which were
conjugated with KLH, and then the anti-PfNSMase antibodies
were purified by affinity chromatography with an antigen peptide-
linked resin. Western blotting was performed using the rabbit
anti-PfNSMase antibodies as the primary antibody and horserad-
ish peroxidase-conjugated goat anti–rabbit IgG (Pierce Chemical
Co.) as the secondary antibody, and visualized with an ECL Kit
(Amersham Pharmacia Biotech). Membrane fraction from the P.
falciparum parasite and bovine brain was prepared as described pre-
viously (27). Protein concentrations were determined by the
method of Lowry et al. (34), using BSA as the standard.
Results
Identification of PfNSM, a Plasmodial Gene Putatively En-
coding an SMase. To identify the gene for plasmodial
SMase, in silico sequence analysis was performed by search-26 P. falciparum Sphingomyelin/Lysocholinephospholipids-Phospholipase C
ing the NCBI Malaria Genetics and Genomics data-
bases (http://www.ncbi.nlm.nih.gov/Malaria) through the
BLAST program with the amino acid sequence of Staphy-
lococcus aureus SMase (GenBank/EMBL/DDBJ accession
no. X13404) as a query. One EST clone PF1350C (Gen-
Bank/EMBL/DDBJ accession no. N97823) and DNA
contig fragment (GenBank/EMBL/DDBJ accession no.
AC005505) in chromosome 12 of P. falciparum was found
to encode a candidate gene for SMase. DNA sequence of
the 1.7 kbp PF1350C clone matches the corresponding ge-
nomic sequence perfectly except for the poly(A) tail. How-
ever, comparison of the genome and PF1350C sequences
suggested that the longest ORF encoded in PF1350C was
not full-length, because there is a Met codon in the ge-
nomic sequence at 13 bp upstream of the 5  terminus of
PF1350C in the same frame of the ORF. To know the
structure of the full-length ORF, we performed 5 -RACE
experiment by using the 3D7 line of P. falciparum as RNA
source. The nucleotide sequence analysis of the DNA frag-
ment obtained from 5 -RACE reveals a  450 base non-
coding sequence before the first Met codon of the putative
ORF. Taken together, the 2.18 kbp cDNA sequence re-
constituted from PF1350C and the 5 -RACE product was
regarded as a cDNA encoding the full-length ORF (Gen-
Bank/EMBL/DDBJ accession no. AF323591). For sim-
plicity, we refer to the locus in the genomic DNA encod-
ing this cDNA as the PfNSM. Sequence analysis of PfNSM
and its cDNA predicts that PfNSM is an intronless gene
Figure 1. Primary structure of P.
falciparum SM/LCPL-PLC. (A) De-
duced amino acid sequence of P. fal-
ciparum SM/LCPL-PLC. (B) Hy-
dropathy profile of the deduced
PfNSM product obtained using
Kite-Doolittle algorithm with a
window size of nineteen (reference
35). (C) Intracellular distribution of
GST-PfNSMase expressed in E. coli.
After centrifugation at 105 g for 1 h,
E. coli cell lysates transfected with
pGEX-PfNSM (lanes 1 and 2) or
pGEX-PfNSMd(2/68) (lanes 3 and
4), were analyzed by Western blot-
ting using anti-PfNSMase antibod-
ies. Lanes 1 and 3, supernatant; lanes 2 and 4, pellet frac-
tion. 2  g protein was loaded in each lane. (D) Multiple
sequence alignment of the SMases from different species.
Sequence alignments were performed with CLUSTAL W
(reference 47) and refined with GeneAlign program (ref-
erence 48) using amino acid sequences in the regions
where significant homology was observed through the
dotplot analysis. The regions in each amino acid sequence
used are PFAL (P. falciparum), 182–278; BCER (B. cereus),
129–225; SAUR (S. aureus), 134–230; LINT (L. interro-
gans), 179–275; HSAP1 (Homo sapiens), 81–181; and
HSAP2 (Homo sapiens), 406–513. Amino acid residues
conserved in all species and more than four species are
highlighted in black and gray, respectively. (E) Phylogenetic tree of SMases. The multiple sequence alignment shown in D was used to make the phylo-
genetic tree through neighbor-joining algorithm with MEGA version 2.2 (reference 38). Scale bar indicates the number of substitutions per site. Boot-
strap values are percentages of 1,000 replications and are shown at the nodes. GenBank/EMBL/DDBJ accession no. for each SMase is in parentheses.
UPGMA also gave similar phylogenetic tree with similar topology.27 Hanada et al.
that encodes a protein of 393 amino acid residues (Fig. 1 A)
with a molecular mass of 46,013 and has 80% A/T content
typical of plasmodial genes (31).
Although SMase activity detected in isolated parasites is
membrane-bound (27), hydropathy profile (35) predicts
that neither signal sequence nor transmembrane region was
present in the deduced PfNSM product (Fig. 1 B). Western
blot analysis showed that the PfNSM product was largely
associated to membrane fraction in E. coli cells when ex-
pressed as a fusion protein with GST, but that its mem-
brane-bound nature was significantly abrogated by deletion
of the 2–68th amino acid residues of the PfNSM product
(Fig. 1 C). These results suggest that a moderately hydro-
phobic region encompassing 12–60 amino acid residues of
the PfNSM product (Fig. 1 B) plays a role in the binding of
this protein to membranes, although other regions might
also be involved in membrane binding. Motif analysis pro-
grams, PSORT (36) and SignalP (37), predict that the
PfNSM product has no cleavable signal peptide sequence.
Phylogenetic analysis conducted using MEGA version 2.2
(38) with the multiple sequence alignment (Fig. 1 D) sug-
gests that the PfNSM sequence is more similar to SMase se-
quences of bacteria than those of human (Fig. 1 E), al-
though P. falciparum is a eukaryote.
Stage-specific Expression of PfNSM. Northern blotting
experiment with three different parasite lines (Honduras-1,
3D7, and Dd2) showed a single hybridized signal at 2.2 kb
(Fig. 2 A), indicating that the PfNSM is indeed transcribed
in intraerythrocytic parasite cells, and ubiquitously ex-
pressed in various P. falciparum strains. The 2.2 kb size de-
tected in Northern blotting is consistent with that of the
PfNSM cDNA described above.
Using a synchronized HB3 parasite line, a 2.2 kb hybrid-
ized signal was likewise detected specifically in trophozo-
ite- and schizont-stage rich sample (Fig. 2 B) in a separate
Northern blot. However, no distinct band was detected in
ring-stage rich sample, though the amount of total RNA
loaded was increased from 4 to 10  g (Fig. 2 B). To further
Figure 2. Stage-specific transcription of
PfNSMase in the intraerythrocytic parasite P.
falciparum. (A) Northern blotting of asyn-
chronous parasite culture. 10  g of total
RNA prepared from asynchronous cultures
of three P. falciparum lines was loaded in each
lane. The ethidium bromide-stained gel
(lanes 1–3) shows the comparable loadings of
RNA. Lane 1 and 4, 3D7; lane 2 and 5,
Honduras-1; lane 3 and 6, Dd2. The posi-
tion of the standard RNA marker (GIBCO
BRL) is shown at the left. The stage distri-
bution for each line is indicated: 3D7, 63%
ring, 26% trophozoite, 11% schizont; Hon-
duras-1, 71% ring, 22% trophozoite, 7% schiz-
ont; and Dd2, 48% ring, 26% trophozoite,
26% schizont. (B) Northern blotting of syn-
chronous parasite culture. 4  g (lanes 1, 2, 5,
and 6) and 10  g (lanes 3, 4, 7, and 8) of to-
tal RNA prepared from different stages of
tightly synchronized culture of HB3 line was
loaded. The ethidium bromide–stained gel
(lanes 1–4) indicates the comparable loadings
of RNA from the different stages at two dif-
ferent concentrations. Lanes 1, 3, 5, and 7,
ring-rich culture (99% ring, 1% trophozoite,
0% schizont); lanes 2, 4, 6, and 8, trophozo-
ite- and schizont-rich culture (0% ring, 86%
trophozoite, 14% schizont). The position of
the standard RNA marker is shown at the
left. (C) RT-PCR experiment. PCR prod-
ucts obtained from different concentrations
of first strand cDNA from various stages of
tightly synchronized parasite culture of
Honduras-1 line were analyzed in 0.8% aga-
rose gel. Lanes 1 and 2, 3 and 4, 5–9, 10–14,
and 15–19 are products obtained from ring,
young trophozoite, mature trophozoite, schiz-
ont, and segmented-schizont, respectively.
Parasite morphology at each stage used is
shown on top. Dilution factors of the first
strand cDNA solution are as follows: lanes 1,
2, 3, 5, 10, and 15, no dilution; lanes 4, 6,
11, and 16, 10-fold; lanes 7, 12, and 17,
100-fold; lanes 8, 13, and 18, 1,000-fold;
lanes 9, 14, and 19, 10,000-fold.28 P. falciparum Sphingomyelin/Lysocholinephospholipids-Phospholipase C
specify the stage when the transcription of PfNSM occurs,
we performed RT-PCR by using the total RNA from
ring, young and mature trophozoite, schizont, and seg-
mented schizont stage parasite cultures. A distinct PCR
product of the expected size could be detected in the sam-
ple starting from young trophozoite stage to the later stages
(Fig. 2 C). In contrast, no PCR product could be detected
in the ring stage sample, although the quality and quantity
of the RNA sample used was enough to amplify a control
PCR product corresponding to the conserved region of
merozoite surface protein-1 gene (Fig. 2 C, lane 1). The
level of the PCR product for PfNSM increased as in-
traerythrocytic development proceeded reaching a maxi-
mum at segmented schizont stage.
Expression of PfNSM Gene in E. coli. To determine
whether PfNSM encodes an SMase, we constructed a re-
combinant plasmid designated pGEX-PfNSM, in which
the coding sequence of PfNSM gene was linked to GST
sequence proceeded by a bacterial expression unit. Soni-
cated lysates of E. coli cells transfected with pGEX-PfNSM
or the empty vector pGEX-6P-2 were assayed for the ac-
tivity of SM hydrolysis under various conditions (Table I).
When assayed under acidic conditions, no activity was de-
tected even in the presence of Zn2 , which activates an
isoform of mammalian acid SMase (20). In contrast, under
assay conditions for a plasmodial neutral SMase dependent
on Mg2  and anionic phospholipids (27), substantial activ-
ity was detected in the lysate from cells transfected with
pGEX-PfNSM, but not with the empty vector. The ac-
tivity of the pGEX-PfNSM-transfected cell lysate was re-
duced to around 1/100 when the exogenous PtdSer was
omitted from the assay. Water-soluble radioactivity liber-
ated from [choline-methyl-14C]SM comigrated with a stan-
dard phosphocholine in TLC (data not shown), indicating
that  PfNSM encodes an SMase belonging to the PLC
type. For simplicity, we tentatively refer to the specific
products of PfNSM and pGEX-PfNSM as PfNSMase and
GST-PfNSMase, respectively.
Almost 100% SMase activity in lysate of E. coli cells
transfected with pGEX-PfNSM was precipitated at high-
speed centrifugation. It is likely that the sedimentation of
the SMase activity was due to the membrane-bound nature
of this enzyme, rather than the formation of an insoluble
aggregation (“inclusion body”) in E. coli, because SMase
activity in the precipitate fraction was efficiently solubilized
by 1% Triton X-100, a nonionic mild detergent (data not
shown). When the membrane fraction of E. coli expressing
GST-PfNSMase was used as the enzyme source, the SMase
activity was linear for at least 30 min, was directly propor-
tional to protein concentrations up to 0.2 mg/ml, showed
an optimum pH at around 7.5, had an apparent Michaelis
constant (Km) value for SM of  90  M, and was Mg2  de-
pendent with a half saturation concentration of  3 mM
(data not shown).
GST-PfNSMase Is Capable of Hydrolyzing LysoPtdCho and
LysoPAF under Detergent-Free Conditions. When assayed
in the presence of 0.1% Triton X-100, hydrolysis of
[14C]lysoPtdCho by GST-PfNSMase was negligible (data
not shown). However, under detergent-free assay condi-
tions, pronounced activity to release radioactive mono-
palmitoylglycerol from [palmitoyl-1-14C]lysoPtdCho was
detected in the membrane fraction of E. coli cells trans-
fected with pGEX-PfNSM, but not with the empty vector
(Fig. 3 A). The lysoPtdCho-PLC activity was Mg2  depen-
dent like SMase activity. The Km value for lysoPtdCho was
determined to be  25   M based on double reciprocal
plots (data not shown). Surprisingly, the lysoPtdCho-PLC
activity in intact membranes did not require the addition of
exogenous PtdSer. LysoPtdCho-PLC activity was also de-
tected in the membrane fraction from parasite cells under
detergent-free conditions, but not under detergent-mixed
micelle conditions (data not shown).
Hydrolysis of 10  M [palmitoyl-1-14C]lysoPtdCho was
strongly competed by sphingosylphosphocholine (“ly-
soSM”) as well as nonradioactive lysoPtdCho (Fig. 3 B),
suggesting that PfNSMase also recognized sphingo-
sylphosphocholine. The activity was moderately com-
peted by PAF and lysoPAF, but unaffected by lysoPtdSer
or lysophosphatidylinositol up to 50  M (Fig. 3 B). Un-
der detergent-free conditions, the membrane fraction ex-
pressing GST-PfNSMase hydrolyzed lysoPAF, but not
PAF (Fig. 3 A). No PLC activity toward PtdCho or
phosphatidylinositol was observed regardless of the pres-
ence of 0.1% Triton X-100 in the assay buffer (unpub-
lished data).
Susceptibility of GST-PfNSMase to Scyphostatin. Previ-
ously we have shown that neutral SMase activity associated
with the membrane fraction from isolated P. falciparum
parasite was inhibited by scyphostatin (27), a compound
that was originally found as an inhibitor of mammalian
neutral SMase (39, 40). The PfNSM encodes the enzyme
exhibiting PLC activity toward SM and LCPL. We tested
Table I. SM Hydrolysis in Lysates of E. coli Cells Transfected 
with pGEX-PfNSM or the Empty Vector
SM hydrolyzed
Assay conditions pGEX-PfNSM
Empty
vector
nmol/mg protein/h
pH 4.8  0.05  0.05
pH 4.8, 10 mM ZnCl2  0.05  0.05
pH 7.5, 10 mM MgCl2 0.061   0.023  0.05
pH 7.5, 10 mM MgCl2, 1 mM PtdSer 5.69   0.29  0.05
Sonicated lysates (25  g protein) of E. coli cells transfected with pGEX-
PfNSM or the empty vector pGEX-6P-2 were incubated with [choline-
methyl-14C]SM in 0.1 M sodium acetate buffer (pH 4.8) containing 0.1%
Triton X-100 in the presence or absence of 10 mM ZnCl2, or in 50 mM
Hepes-NaOH buffer (pH 7.5) containing 0.1% Triton X-100 and 10
mM MgCl2 in the presence or absence of 1 mM bovine brain PtdSer at
37 C for 30 min. The water-soluble radioactivity released from [14C]SM
was measured as described under Materials and Methods. The mean
values   SD from triplicate experiments are shown.29 Hanada et al.
if the PLC activity of this enzyme was inhibited by scy-
phostatin. Scyphostatin inhibited PLC activity toward SM
in a dose-dependent manner with an ID50 value of  3
 M (Fig. 4), similar to the SMase activity detected in iso-
lated parasite membranes (27). Likewise, scyphostatin in-
hibited PLC activities toward lysoPtdCho and lysoPAF
with ID50s of 3–5  M (Fig. 4). The ID50 value of scypho-
statin to neutral SMase activity of bovine brain membrane
was  15  M (Fig. 4), which is  5-fold higher than that
of plasmodial SMase.
Scyphostatin Inhibits the Intraerythrocytic Proliferation of P.
falciparum. We then examined the effect of scyphostatin
on the in vitro culture of P. falciparum to implicate the
PLC activities associated with PfNSM product to the in-
traerythrocytic proliferation of parasite cells. For this, three
parasite lines were used: FCR3 line resistant to chloro-
quine, Honduras-1 line resistant to pyrimethamine and cy-
cloguanyl, and 3D7 line sensitive to those conventional
antimalarial drugs. As shown in Fig. 5 A, the growth of all
parasite lines tested was inhibited by scyphostatin in a
dose-dependent manner with 50% inhibition observed at
8, 6, and 6.5  M for 3D7, Honduras-1, and FCR3, re-
spectively. ID50s for the parasite growth are close to those
for SM/LCPL-PLC activities (Fig. 4). PPMP, a ceramide-
related compound that inhibits the SM synthase activity as
well as intraerythrocytic proliferation of P. falciparum (7,
27), showed 50% growth inhibition at  6  M (data not
shown). Difference in ID50 values from the previous report
(7) may be partly due to the purity of PPMP and/or the
culture condition used.
Selective Effect of Scyphostatin on the Intraerythrocytic Devel-
opment of P. falciparum. To examine the effect of scypho-
statin on the intraerythrocytic development of P. falciparum,
we monitored the morphological changes of tightly syn-
chronized parasites within 4 h life span, which were treated
with scyphostatin at different stages. PPMP was used for
comparison. Honduras-1 line was chosen as the representa-
tive parasite since all parasite lines tested so far showed sim-
ilar ID50 values. A serum-free medium supplemented with
1  M scyphostatin or 5  M PPMP ( ID90s from the mi-
croscopic assay in Fig. 5 B) was used to obtain a reproduc-
ible intraerythrocytic development. As shown in Fig. 6, in
an inhibitor-free control culture medium containing vehi-
cle solvent (0.1% DMSO), the parasite developed normally
and entered the next cycle at 52 h with  5.6% parasitemia
of newly formed ring (lane 1). When 1  M scyphostatin
was added at the initial ring stage (0 h), parasite cells devel-
Figure 3. LCPL-PLC activity in the membrane fraction of E. coli cells
transfected with pGEX-PfNSM. (A) LysoPtdCho-, lysoPAF-, and PAF-
PLC activities. Membranes (5  g protein) from E. coli cells transfected
with the indicated plasmids were incubated in 50  l HM buffer (50 mM
Hepes-NaOH, pH 7.5, and 10 mM MgCl2) containing 10  M of various
radioactive substrates at 37 C for 30 min. The amount of hydrolyzed sub-
strates was determined as described under Materials and Methods. The data
are means   SD from three experiments. (B) Competition of lysoPtdCho-
PLC activity with various lipids. The membrane fraction from pGEX-
PfNSM-transfected E. coli (5  g protein) was incubated in 50  l of 50
mM Hepes-NaOH (pH 7.5) containing 10 mM MgCl2, 10  M [palmi-
toyl-1-14C]lysoPtdCho, and various concentrations of nonradioactive
competitors at 37 C for 30 min. The radioactivity of monopalmitoylglyc-
erol produced was determined as described under Materials and Methods.
The data shown are the percentages of the mean activity determined in
the absence of competitors. Filled circles, lysoPtdCho; open circles, lyso-
PAF, filled squares, PAF; open squares, sphingosylphosphocholine; filled
triangles, lysoPtdSer; open triangles, lysophosphatidylinositol.
Figure 4. Effect of scyphostatin on SM/LCPL-LPC activity. Mem-
brane fraction prepared from GST-PfNSMase-expressing E. coli and bo-
vine brain (0.5 mg protein/ml each) was incubated with various concen-
trations of scyphostatin in HSEI buffer for 30 min on ice. SMase activity
of plasmodial (filled circles) and mammalian enzyme (open circles) was
determined in the presence of 0.1% Triton X-100, and activities of
lysoPtdCho-PLC (filled squares) and lysoPAF-PLC (filled triangles) were
determined under detergent-free conditions as described under Materials
and Methods. The values of the activity are shown as the percentage of
the control activity determined in the absence of the drug.30 P. falciparum Sphingomyelin/Lysocholinephospholipids-Phospholipase C
oped to mature trophozoites, but could not develop to
schizonts, exhibiting a slightly bigger but less stained tro-
phozoite-like morphology. These trophozoite-like struc-
tures neither developed further nor formed new ring stage
parasites even after 52 h cultivation (lane 2). A similar effect
on parasite morphology was observed when the scyphosta-
tin was added at the early-trophozoite stage (24 h; lane 4).
Addition of scyphostatin at the mid- and late-trophozoite
stages (28 and 32 h) resulted in an increase in the para-
sitemia of newly formed rings to 1–3% (lanes 6 and 8).
Conversely, when added at the schizont (36 h) and seg-
mented schizont (40 h) stages, the parasitemia of rings at 52 h
reached the level comparable to that of the inhibitor-free
control (lanes 10 and 12). These results indicate that 1  M
scyphostatin has no or little effect on the stage progression
from ring to trophozoite as well as that from schizont to
the next ring stage, but impaired specifically the maturation
of trophozoite into schizont. Interestingly, the time for scy-
phostatin to start exerting the effect on the intraerythro-
cytic development is consistent with the time to start tran-
scribing the PfNSM (Figs. 2 C and 6).
Similar to scyphostatin, PPMP impaired the stage pro-
gression from trophozoite to schizont, though, in this cul-
ture condition, the period PPMP exerts its effect was
slightly broader than previously reported (7). The para-
sitemia of newly formed ring was severely affected when
PPMP was added from 24–36 h (lanes 5, 7, 9, and 11). Un-
like scyphostatin, the typical hemozoin formation was not
observed in parasitized erythrocytes upon the addition of
PPMP at ring stage (0 h; lane 3). These results imply that
PPMP impairs the stage progression from ring to trophozo-
ite as well.
Discussion
In this study, we identified a plasmodial gene (named
PfNSM) encoding a neutral SMase. As far as we know, this
is the first report in the molecular cloning of a protozoan
SMase. When GST-PfNSMase, a fusion protein of the
PfNSM product with GST, was expressed in E. coli, the
cells produced SMase activity liberating phosphocholine
from SM. Enzyme properties of GST-PfNSMase are con-
sistent in various respects with those of SMase detected in
P. falciparum-infected erythrocytes and isolated parasites.
They require Mg2  and anionic phospholipids for SMase
activity in vitro, and are efficiently inhibited by scypho-
statin (27; Fig. 4). The optimum pH of the activity is
around pH 7.5, and the apparent Km for SM is 50–100  M.
Further characterization of GST-PfNSMase expressed in E.
coli has revealed that the plasmodial SMase is capable of hy-
drolyzing LCPLs such as lysoPtdCho and lysoPAF in vitro
(Fig. 3). The membrane fraction from P. falciparum parasites
also retained this LCPL-PLC activity (data not shown).
Henceforth, we refer to the PfNSM product as a plasmodial
SM/LCPL-PLC.
LCPL-PLC activity of the plasmodial SM/LCPL-PLC
was hardly detected in the presence of 0.1% Triton X-100,
although the same enzyme source showed a high activity of
SMase in the presence of the detergent. It is currently un-
known as to why PLC activities to different substrates by
the same enzyme are differently affected by detergents. Be-
cause both activities of SMase and LCPL-PLC that are as-
sociated with the protein encoded in the PfNSM are simi-
larly inhibited by scyphostatin (Fig. 4), it is unlikely that
this enzyme has two catalytic sites and each of them medi-
ates one of two reactions. Efficient hydrolysis of lysoPtd-
Cho and lysoPAF under detergent-free condition was also
observed in a mammalian SMase (nSMase-1; reference 19).
Not only the plasmodial SM/LCPL-PLC but also bacterial
SMases and a mammalian SMase (nSMase-1) are capable of
hydrolyzing lysoPtdCho (19, 41; Fig. 3 A). However, the
ratios of lysoPtdCho-PLC activity determined under deter-
gent-free conditions to SMase activity determined under
the mixed micelle conditions are 0.5 or more for the plas-
modial SM/LCPL-PLC and mammalian nSMase-1, but
Figure 5. Parasite growth inhibition by scyphostatin. (A) In vitro sus-
ceptibility of parasite lines to scyphostatin in a standard medium. The val-
ues are expressed as the percentage of the [3H]hypoxanthine incorpora-
tion into parasites treated with scyphostatin over those without treatment.
The DMSO content in the assay media did not exceed 0.6%, which did
not show any effect on the [3H]hypoxanthine incorporation into para-
sites. The mean values of triplicates from two independent experiments
were used for each plot. Filled circles, 3D7; filled triangle, Honduras-1;
filled squares, FCR3. (B) In vitro susceptibility of Honduras-1 line to scy-
phostatin (circles) or PPMP (triangles) in a serum-free medium was ex-
amined through either [3H]hypoxanthine incorporation assay (filled sym-
bols) or microscopic assay (open symbols).31 Hanada et al.
 0.01 for bacterial SMases (this study, and references 19
and 41).
The ID50 values of scyphostatin and PPMP for the para-
site growth in a serum-free medium determined by the
[3H]hypoxanthine incorporation assay are 1.2 and 3.5  M,
respectively, whereas by microscopic assay those of scy-
phostatin and PPMP are 0.2 and 0.6  M, respectively (Fig.
5 B). In the microscopic analysis, parasitized erythrocyte
exhibiting an abnormal trophozoite-like morphology and a
tiny ring- or early trophozoite-like morphology observed
in the culture treated with scyphostatin (at 52 h in lane 2,
Fig. 6) and PPMP (at 52 h in lane 3, Fig. 6), respectively,
Figure 6. Effect of scyphostatin and PPMP on the intraerythrocytic development of Plasmodium falciparum. Parasite cells were treated with 1  M scy-
phostatin or 5  M PPMP at different stages. Lane 1, control medium containing 0.1% DMSO; lanes 2, 4, 6, 8, 10, and 12, medium containing 1  M
scyphostatin; lanes 3, 5, 7, 9, 11 and 13, medium containing 5  M PPMP. The parasite culture was transferred from the control medium into the me-
dium containing inhibitor in place of DMSO at 24 h (lanes 4 and 5), 28 h (lanes 6 and 7), 32 h (lanes 8 and 9), 36 h (lanes 10 and 11), and 40 h (lanes 12
and 13). Each panel shows the major morphology of the intraerythrocytic parasite in each treatment at the indicated time. Inset shows the other mor-
phology that when observed, comprises  50% of the major one. However, in some occasions, no major morphology was observed. The percentage in-
dicated at the left is the parasitemia of newly formed rings at 52 h. Mean values from duplicate slides are shown, results are reproducible based on two
independent experiments.32 P. falciparum Sphingomyelin/Lysocholinephospholipids-Phospholipase C
were evident at 0.1–1  M scyphostatin and 0.3–3  M
PPMP. These morphologies, however, could not be ob-
served at 96 h with concentrations  0.1  M scyphostatin
and  2  M PPMP in a similar assay condition (data not
shown). The parasites exhibiting such abnormal morpholo-
gies might be committed to cell death, but still retain meta-
bolic activity with respect to hypoxanthine incorporation
into nucleic acid, thereby giving differences in ID50 values
depending on assay methods (Fig. 5 B).
Transcription of PfNSM is initiated from the young tro-
phozoite stage and becomes most active in segmented schiz-
onts (Fig. 2 C), and scyphostatin impairs specifically the
maturation of trophozoite into schizont during the in-
traerythrocytic development of P. falciparum (Fig. 6). This
good correlation of the time for the PfNSM transcription
and the developmental stage on which scyphostatin exerts
its effect leads us to suggest that the inhibition of the in-
traerythrocytic development of the parasite results from the
inhibition of the plasmodial SM/LCPL-PLC activity.
Lauer et al. (7) indicated that PPMP inhibits SM synthase
activity associated with P. falciparum cells, and also inhibits
proliferation of the parasite in vitro. PPMP does not inhibit
plasmodial SM/LCPL-PLC activity, while scyphostatin
does not inhibit SM synthase activity, indicating that the
target enzymes of the two inhibitors differ (27). The stage
progression influenced by scyphostatin overlaps with that
of PPMP (progression from trophozoite to schizont), al-
though the stage influenced by scyphostatin is narrower.
Parasites treated with both inhibitors at the trophozoite
stage show similar morphological changes (Fig. 6). We as-
sume that a certain functional linkage to maintain the nor-
mal intraerythrocytic development at least in the matura-
tion of trophozoite into schizont of P. falciparum might
exist between SM synthase, the target of PPMP, and SM/
LCPL-PLC, the target of scyphostatin. The knowledge ob-
tained in this study together with previous studies (7, 27)
would emphasize the importance of the enzymes involved
in SM metabolism as rational targets for malaria chemo-
therapy, although the development of specific inhibitors to
plasmodial enzymes is needed in this direction. Interest-
ingly, the ID50 value of scyphostatin to bovine brain SMase
is  5-fold higher than that of plasmodial SMase (Fig. 4),
indicating the possibility that derivation of scyphostatin
leads to more selective or specific inhibitors to plasmodial
SM/LCPL-PLC.
Although physiological and pathological roles of the
SM/LCPL-PLC in P. falciparum cells remain unclear, there
are several possible roles. First, as we have been proposing
(reference 27, and above), the plasmodial SM/LCPL-PLC
might degrade host-derived SM to supply the parasite with
ceramide, which would modulate the cell cycle progression
of intraerythrocytic parasites and/or would be used for re-
synthesis of SM within parasitized erythrocytes. In this re-
gard, we have proposed the possibility that the host-cell
SM is accessible to the plasmodial SM/LCPL-PLC through
the tubovesicular membrane structure (27). This proposal is
supported by the recent finding demonstrated by Lauer et
al. (42) that degradation of externally supplied sphingomy-
elin analogs in parasitized-erythrocytes is inhibited when
cells were treated with PPMP which impaired the forma-
tion of the tubovesicular membrane structure. Note that
the stage-specific transcription of PfNSM gene correlates
well with the C6-NBD-SM hydrolyzing activity levels (this
study, and reference 42). Second, the plasmodial SM/
LCPL-PLC might degrade host-derived lysoPtdCho to
supply the parasites with phosphocholine and/or monoa-
cylglycerol for their efficient intraerythrocytic growth since
lysoPtdCho is abundant in the human plasma, especially in
forms associated with lipoproteins (43, 44). Third, the plas-
modial SM/LCPL-PLC might be implicated to detoxify
LCPLs. It has been recently shown that human lipoproteins
treated with bee venom phospholipase A2 are highly toxic
to the in vitro culture of P. falciparum (45). As the most
abundant type of phospholipids associated with lipoproteins
is PtdCho (43, 44), treatment of lipoproteins with phos-
pholipase A2 is predicted to enhance greatly the level of
lysoPtdCho. If so, the plasmodial SM/LCPL-PLC could be
involved in the detoxification of potentially harmful
lysoPtdCho. Finally, a previous study showed that the level
of plasma lysoPAF in patients with severe malaria is re-
duced to  10% from the normal level, and suggested that
the reduction of the plasma lysoPAF level was due to the
increased production of PAF in malaria patients (46). Our
finding in this study raises an alternative, but not mutually
exclusive, explanation that an enhanced degradation of
lysoPAF through plasmodial SM/LCPLs-PLC results to a
decrease in the plasma lysoPAF level.
Success in the identification of the gene for P. falciparum
SM/LCPL-PLC and production of the plasmodial SM/
LCPL-PLC in E. coli as a recombinant protein could facili-
tate elucidation of the physiological functions of this en-
zyme and create invaluable tools that can be exploited to
localize this enzyme within parasitized erythrocytes, to
study for the regulation of gene expression, and to perform
transfection experiments.
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